Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.

Kanta Devi; Muhammad Usman Shaikh; Natasha Bahadur Ali; Salman Naseem Adil; Maria Khan; Salman Muhammad Soomar

doi:10.1016/j.lrr.2021.100284

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.

Kanta Devi, Muhammad Usman Shaikh, Natasha Bahadur Ali, Salman Naseem Adil, Maria Khan, Salman Muhammad Soomar

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.

Original language	English
Article number	100284
Journal	Leukemia Research Reports
Volume	16
DOIs	https://doi.org/10.1016/j.lrr.2021.100284
Publication status	Published - Jan 2021

Keywords

Diffuse large B-cell lymphoma
Non-hodgkin lymphoma
R-CHOP
R-DA-EPOCH
Survival

Access to Document

10.1016/j.lrr.2021.100284

Cite this

@article{2d4d71f5a15945dc9852e3dcf69a1ae3,

title = "Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.",

abstract = "In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.",

keywords = "Diffuse large B-cell lymphoma, Non-hodgkin lymphoma, R-CHOP, R-DA-EPOCH, Survival",

author = "Kanta Devi and Shaikh, {Muhammad Usman} and Ali, {Natasha Bahadur} and Adil, {Salman Naseem} and Maria Khan and Soomar, {Salman Muhammad}",

note = "Publisher Copyright: {\textcopyright} 2021",

year = "2021",

month = jan,

doi = "10.1016/j.lrr.2021.100284",

language = "English",

volume = "16",

journal = "Leukemia Research Reports",

issn = "2213-0489",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP

T2 - A single-center experience.

AU - Devi, Kanta

AU - Shaikh, Muhammad Usman

AU - Ali, Natasha Bahadur

AU - Adil, Salman Naseem

AU - Khan, Maria

AU - Soomar, Salman Muhammad

PY - 2021/1

Y1 - 2021/1

N2 - In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.

AB - In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.

KW - Diffuse large B-cell lymphoma

KW - Non-hodgkin lymphoma

KW - R-CHOP

KW - R-DA-EPOCH

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85120432634&partnerID=8YFLogxK

U2 - 10.1016/j.lrr.2021.100284

DO - 10.1016/j.lrr.2021.100284

M3 - Article

AN - SCOPUS:85120432634

SN - 2213-0489

VL - 16

JO - Leukemia Research Reports

JF - Leukemia Research Reports

M1 - 100284

ER -

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this